Insulet (NASDAQ:PODD) Stock Price Expected to Rise, Barclays Analyst Says

Insulet (NASDAQ:PODD) had its price target lifted by Barclays from $220.00 to $234.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Several other equities research analysts also recently commented on PODD. Piper Sandler upped their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. BTIG Research lifted their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, UBS Group upped their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Trading Down 0.8 %

PODD traded down $2.12 during trading on Monday, reaching $273.58. The company had a trading volume of 31,272 shares, compared to its average volume of 778,792. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet has a 12-month low of $156.00 and a 12-month high of $279.40. The company has a market cap of $19.18 billion, a price-to-earnings ratio of 47.21, a PEG ratio of 5.00 and a beta of 1.22. The firm’s 50-day simple moving average is $233.46 and its 200 day simple moving average is $205.26.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PODD. Marshall Wace LLP bought a new position in shares of Insulet in the 2nd quarter valued at approximately $99,978,000. Baillie Gifford & Co. raised its stake in shares of Insulet by 30.8% in the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after acquiring an additional 443,783 shares in the last quarter. Mizuho Securities USA LLC raised its stake in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after acquiring an additional 320,416 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Insulet by 206.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock valued at $73,632,000 after acquiring an additional 289,591 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after acquiring an additional 169,506 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.